Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

類似資料

• Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
  著者:: Richardson, P. G., 等
  出版事項: (2018)
• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
  著者:: Paludo, Jonas, 等
  出版事項: (2017)
• Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
  著者:: Richardson, Paul G., 等
  出版事項: (2013)
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
  著者:: Richardson, Paul G., 等
  出版事項: (2010)
• Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
  著者:: Dimopoulos, Meletios, 等
  出版事項: (2020)